Last updated: 21 July 2019 at 11:32pm EST

Mary Elizabeth Potthoff Net Worth



Mary Potthoff CRIS stock SEC Form 4 insiders trading

Mary has made over 7 trades of the Curis Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently Mary exercised 21,875 units of CRIS stock worth $42,875 on 3 December 2004.

The largest trade Mary's ever made was exercising 25,489 units of Curis Inc stock on 16 June 2004 worth over $61,938. On average, Mary trades about 11,648 units every 30 days since 2003.

You can see the complete history of Mary Potthoff stock trades at the bottom of the page.



What's Mary Potthoff's mailing address?

Mary's mailing address filed with the SEC is , , , , .

Insiders trading at Curis Inc

Over the last 24 years, insiders at Curis Inc have traded over $10,321,234 worth of Curis Inc stock and bought 10,678,594 units worth $25,596,192 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Discovery Technologies Ltd ... a James R Mcnab. On average, Curis Inc executives and independent directors trade stock every 62 days with the average trade being worth of $811,553. The most recent stock trade was executed by James E Dentzer on 27 January 2022, trading 5,500 units of CRIS stock currently worth $17,160.



What does Curis Inc do?

curis is a publicly-traded biotechnology company (nasdaq: cris) focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. curis’s pipeline of drug candidates includes cudc-907, which is currently being investigating in clinical trials in patients with relapsed or refractory diffuse large b-cell lymphoma with alterations in the myc oncogene. curis is also engaged in a broad collaboration with aurigene in the areas of immuno-oncology and precision oncology. as part of this collaboration, curis has exclusive licenses to oral small molecule antagonists of the pd1 and vista pathways, including pdl1/vista antagonist ca-170, and oral small molecule antagonists of the pd1 and tim3 pathways, including pdl1/tim3 antagonist ca-327, as well as to molecules designed to inhibit the irak4 kinase, including ca-4948. ca-170 is currently undergoing testing in a phase 1 trial in patients with advanced solid tumors and lymphomas. ca-4948 is currentl



Complete history of Mary Potthoff stock trades at Curis Inc

Osoba
Trans.
Transakce
Celková cena
Mary Elizabeth Potthoff
Vice President a Hlavní právník
Využití opce $42,875
3 Dec 2004
Mary Elizabeth Potthoff
Vice President a Hlavní právník
Využití opce $5,000
3 Sep 2004
Mary Elizabeth Potthoff
Vice President a Hlavní právník
Využití opce $13,999
21 Jun 2004
Mary Elizabeth Potthoff
Vice President a Hlavní právník
Využití opce $61,938
16 Jun 2004
Mary Elizabeth Potthoff
Vice President a Hlavní právník
Využití opce $20,493
8 Jun 2004
Mary Elizabeth Potthoff
Vice President a Hlavní právník
Využití opce $19,464
16 Jan 2004
Mary Elizabeth Potthoff
Vice President a Hlavní právník
Využití opce $16,000
13 Jan 2004


Curis Inc executives and stock owners

Curis Inc executives and other stock owners filed with the SEC include: